ELECTRONIC ARTICLE |



* Departments of Pediatrics
Radiology
|| Pharmacy, Centre Hospitalier Universitaire de Québec, Université Laval, Quebec, Quebec, Canada
Department of Pediatrics, Hôpital Sainte-Justine, Université de Montréal, Montreal, Quebec, Canada
Objective.This randomized, controlled trial was designed to determine the efficacy of inhaled fluticasone propionate on oxygen therapy weaning in a population of preterm infants who were born at <32 weeks of gestation and experienced moderate bronchopulmonary dysplasia (BPD).
Methods.Thirty-two infants who were
32 weeks of gestation, had moderate BPD that required supplemental oxygen (fraction of inspired oxygen
0.25), and were aged between 28 and 60 days were randomized. Fluticasone propionate 125 µg twice daily for 3 weeks and once daily for a fourth week was delivered to infants who weighed between 500 and 1200 g. The dosage was doubled for infants who weighed
1200 g.
Results.Compared with placebo, treatment had no effect on either duration of supplemental O2 therapy or ventilatory support as assessed by survival analysis. At 28 days, a trend toward a lower cortisol/creatinine ratio in the treatment group was noted compared with placebo (25.1 ± 18.9 vs 43 ± 14.4). In the fluticasone group at 28 days, the systolic arterial pressure (78 ± 3 vs 68 ± 3 mm Hg) and diastolic arterial pressure (43 ± 3.4 mm Hg vs 38 ± 2.0 mm Hg) were higher compared with baseline fluticasone values. The chest radiograph score was lower than baseline (2.8 ± 1.4 vs 3.7 ± 2.2) in the fluticasone group at 28 days. This study has a statistical power of 1.0 to detect a significant difference in the duration of oxygen supplementation of >21 days between the study groups.
Conclusion.We conclude that fluticasone propionate reduces neither supplemental O2 use nor the need for ventilatory support in this patient population. However, fluticasone does have a positive radiologic effect in lowering chest radiograph scores. In addition, our data point to a possible association among inhaled fluticasone treatment and higher arterial blood pressure. Thus, the results of this investigation do not support the use of inhaled corticosteroids in the treatment of oxygen-dependent infants who have established moderate BPD.
Key Words: neonatal bronchopulmonary dysplasia clinical trial glucocorticoids oxygen inhalation therapy
Abbreviations: BPD, bronchopulmonary dysplasia FIO2, fraction of inspired oxygen
This article has been cited by other articles:
![]() |
E. Baraldi and M. Filippone Chronic Lung Disease after Premature Birth N. Engl. J. Med., November 8, 2007; 357(19): 1946 - 1955. [Full Text] [PDF] |
||||
![]() |
D. Kohler, P. Haidl, D. Dellweg, L. Bont, J. L.L. Kimpen, M. J.J. Ermers, E. Baraldi, M. Filippone, T. Guilbert, F. D. Martinez, et al. Inhaled corticosteroids and children. N. Engl. J. Med., August 10, 2006; 355(6): 624 - 624. [Full Text] [PDF] |
||||